Target Audience

If you are a pharmacist, physician, educator, scientist, administrator, student, resident, fellow, nurse practitioner or other healthcare professional involved in the comprehensive medication management of patients with psychiatric and/or neurologic disorders, we invite you to attend the CPNP Annual Meeting. As a practitioner in psychiatry and neurology, you can grow and improve in your specialty area. The CPNP Annual Meeting also benefits you in your ever-increasing role in assuring appropriate drug use, providing overall pharmacotherapy management and enhancing positive outcomes.  More importantly, the Annual Meeting provides you the opportunity to interact and share experiences with your peers regarding areas of common interest.

Continuing Education Credit

ACPE Credit

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2013 Annual Meeting will provide up to 15.75 contact hours (1.575 CEUs) of knowledge- and application-based continuing education credit from CPNP approved programming. The pre-meeting workshop is provided for an additional 3.5 contact hours (0.35 CEUs) and when combined with all other CPNP programming, allows for a maximum achievable 19.25 contact hours (1.925 CEUs). Industry supported symposia offered at the Annual Meeting offer additional ACPE credit.

To earn credit, participants must participate, verify their attendance at the programming and complete evaluations and self-assessment questions. CPNP reports to CPE Monitor within 1 month of the event and provides transcripts online on the CPNP website.

Nursing Credit

ACPE and ACCME approved contact hours are accepted for ANCC Certification Renewal (as quoted on the ANCC website): “Other health disciplines' continuing education hours may be used if the content is applicable to your area of certification. ACPE and ACCME are specifically listed as approved credit types.

Goals and Practice Gap

The CPNP Annual Meeting has been designed to bridge the perceived "practice gap" between current knowledge and practice in a number of areas of neuropsychiatry. Published psychiatric guidelines serve as a synthesis of the available evidence base, but there is often disparities seen in clinic practice when compared to these guidelines. Academic Detailing combined with clinical informatics tools for provider audit and feedback can bridge this information gap and allow for action by the healthcare team to improve patient outcomes and promote evidence-based care in treating mental illness. Another process, drug repositioning and repurposing, capitalizes on the fact that drugs often interact with secondary targets, producing effects that may be beneficial. These processes can assist in linking current knowledge about neuropsychiatric medications and disorders to develop new knowledge and treatments.

Another area that the CPNP Annual Meeting will address is the treatment of delirium and the use of antipsychotics in dementia. With the recent recommendations by CMS to reduce antipsychotic medication use by 15% in nursing home settings, alternative treatment options and pearls for decreasing usage of antipsychotics in geriatric population must be explored by practitioners.  

Post-Traumatic Stress Disorder (PTSD) is a complicated disorder with many co-occurring symptoms and sequelae. PTSD is the most common mental health diagnosis and is frequently seen in veteran populations especially combat veterans. This meeting will also address the management of PTSD and the sleep disorders associated with PTSD, which will serve as a platform to optimizing the care of this debilitating disorder.

Overall Learning Objectives

  1. Apply the Chronological Assessment of Suicide Events (CASE) approach as a sensitive and rapid method of uncovering suicidal ideation and intent.
  2. Evaluate evidence-based literature regarding treatment of opioid dependency during pregnancy with buprenorphine or methadone.
  3. Evaluate the evidence supporting the use of antipsychotics as monotherapy or in combination with traditional mood stabilizers in the management of mania and depression.
  4. Apply the principles of the Medication Interest Model.
  5. Report the current evidence regarding the effectiveness of different medications and psychotherapies for post-traumatic stress disorder (PTSD).
  6. Evaluate the available literature on the pharmacologic treatment of schizoaffective disorder.
  7. Describe the effects of prazosin in PTSD to clinical situations.
  8. Compare the efficacy of pharmacologic treatments, cognitive behavioral therapy, and other nonpharmacologic strategies for obsessive-compulsive disorder.
  9. Discuss the pharmacological and legal aspects, clinical effects, and medical management of synthetic drugs of abuse.
  10. Review the changes in the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) from the DSM-IV and the implications of these changes on research and clinical practice.
  11. Explain how to manage neuroleptic malignant syndrome and serotonin toxicity.
  12. Explain the clinical significance, risk factors and associated outcomes of delirium in critically ill patients.
  13. Discuss the benefits and risks of deep brain stimulation for Parkinson’s disease and essential tremor.
  14. Describe benefits and challenges of implementing academic detailing to promote evidence-based care in treating mental illness.
  15. Outline the new Centers for Medicare and Medicaid Services recommendations and discuss alternative treatment options for decreasing usage of antipsychotics in the geriatric population.
  16. Assess the clinical trials of agents approved to treat movement disorders associated with Huntington’s disease.
  17. Outline how publicly available molecular measurements can be used to find new uses for existing medications.
  18. Discuss the potential role of social media in clinical practice.


Business casual attire is recommended throughout the Annual Meeting.